Advanced search
Start date
Betweenand

Equine tumor: proteomic analysis

Grant number: 18/20677-9
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): November 01, 2018
Effective date (End): March 31, 2021
Field of knowledge:Biological Sciences - Biochemistry - Molecular Biology
Cooperation agreement: GlaxoSmithKline
Principal researcher:Ana Marisa Chudzinski-Tavassi
Grantee:Marcus Vinicius Buri
Home Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
Associated research grant:15/50040-4 - Rational approach for searching molecular targets involved in inflammatory events and cell survival, AP.PCPE

Abstract

Melanoma is one type of cancer which incidence is increasing overtime. Alongside with high rate of mortality, manly due to propensity to form metastasis and resistance to any available therapies, leads to poor clinical prognosis. Therefore, is an urgent need to better understand the genetic and molecular events involved in the etiology of this cancer as well as the discovery of novel therapeutic targets. Metastatic melanoma also has high incidence in gray horses, sharing similarity to human melanoma such as different molecular alterations accompanying tumorigenesis, and limited therapeutic options in metastatic stage. In this setting, equine malignant melanoma (EMM) can be an useful approach to translational melanoma studies. Researching for new compounds, Amblyomin-X, a Kunitz-type FXa inhibitor, showed great results against some tumors. To identify new targets involved in Amblyomin-X response against in vitro cell cultures and in vivo tumoral microenvironment, proteomic analysis will be performed by bottom-down mass spectroscopy in order to investigate differential protein expressions profiles. Studies on inflammatory mediators release, signaling pathways, cellular proliferation, molecules and gene expression, among others will also be performed.